Aquestive Therapeutics, Inc. AQST Contract with Customer, Asset, after Allowance for Credit Loss
Contract with Customer, Asset, after Allowance for Credit Loss at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNet.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s contract with customer, asset, after allowance for credit loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s contract with customer, asset, after allowance for credit loss?
- Aquestive Therapeutics, Inc. (AQST) reported contract with customer, asset, after allowance for credit loss of $445K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s contract with customer, asset, after allowance for credit loss changed year-over-year?
- Aquestive Therapeutics, Inc.'s contract with customer, asset, after allowance for credit loss decreased by 38.0% year-over-year, from $718K to $445K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s contract with customer, asset, after allowance for credit loss?
- Over 3 years (2020 to 2025), Aquestive Therapeutics, Inc.'s contract with customer, asset, after allowance for credit loss has grown at a -41.2% compound annual growth rate (CAGR), from $3.08M to $627K.